Atlas Trials

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Clinical trial NCT03204734 · UNKNOWN

Trial details

NCT number
NCT03204734
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2016-01-01
Primary completion
2020-12-30
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.